A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer.
Beatrice StubendorffKerstin WilhelmKathleen PosseltJames CattoArndt HartmannSimone BertzSusanne FüsselVladimir NovotnyMarieta TomaMieczyslaw GajdaJan LehmannHeiko WunderlichMarc-Oliver GrimmMichael StöckleKerstin JunkerPublished in: Journal of cancer research and clinical oncology (2019)
We identified a methylation marker panel suitable to differentiate between patients with positive and negative lymph nodes at time of cystectomy. This enables a risk assessment for patients who potentially benefit from extended lymph node resection as well as from neoadjuvant chemotherapy and could improve the survival rates. Furthermore, we examined the impact of putative markers on tumor behavior. Hence, KISS1R and SEPT9 could represent a starting point for the development of novel therapy approaches.
Keyphrases
- neoadjuvant chemotherapy
- lymph node
- risk assessment
- muscle invasive bladder cancer
- genome wide
- sentinel lymph node
- human health
- dna methylation
- heavy metals
- squamous cell carcinoma
- small cell lung cancer
- copy number
- gene expression
- locally advanced
- early stage
- mesenchymal stem cells
- climate change
- transcription factor
- minimally invasive
- smoking cessation
- genome wide analysis